116 related articles for article (PubMed ID: 20664555)
1. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
Kurata M; Okura T; Irita J; Enomoto D; Nagao T; Jotoku M; Miyoshi K; Desilva VR; Higaki J
J Hum Hypertens; 2011 May; 25(5):334-9. PubMed ID: 20664555
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
3. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
4. The relationship between osteopontin and adiponectin in patients with essential hypertension.
Kurata M; Okura T; Irita J; Enomoto D; Nagao T; Jotoku M; Miyoshi K; Higaki J
Clin Exp Hypertens; 2010; 32(6):358-63. PubMed ID: 21028999
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Zanchetti A; Julius S; Kjeldsen S; McInnes GT; Hua T; Weber M; Laragh JH; Plat F; Battegay E; Calvo-Vargas C; Cieśliński A; Degaute JP; Holwerda NJ; Kobalava J; Pedersen OL; Rudyatmoko FP; Siamopoulos KC; Störset O
J Hypertens; 2006 Nov; 24(11):2163-8. PubMed ID: 17053536
[TBL] [Abstract][Full Text] [Related]
7. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Ke YS; Tao YY; Yang H; Yu GH
Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
[TBL] [Abstract][Full Text] [Related]
8. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
[TBL] [Abstract][Full Text] [Related]
9. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
10. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
11. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Fogari R; Zoppi A; Derosa G; Mugellini A; Lazzari P; Rinaldi A; Fogari E; Preti P
J Hum Hypertens; 2007 Mar; 21(3):220-4. PubMed ID: 17215848
[TBL] [Abstract][Full Text] [Related]
12. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
Unlu M; Karaman M; Ay SA; Balta S; Cakar M; Demirkol S; Celik T; Arslan E; Demirbas S; Turker T; Yaman H; Bulucu F; Sağlam K
Clin Exp Hypertens; 2013; 35(6):418-23. PubMed ID: 23148500
[TBL] [Abstract][Full Text] [Related]
13. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Fogari R; Malamani G; Corradi L; Mugellini A; Preti P; Zoppi A; Derosa G
Adv Ther; 2010 Jan; 27(1):48-55. PubMed ID: 20174905
[TBL] [Abstract][Full Text] [Related]
14. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
[TBL] [Abstract][Full Text] [Related]
15. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Xie QY; Wang YJ; Sun ZL; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
17. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
18. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
[TBL] [Abstract][Full Text] [Related]
19. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
